A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma

Detalles Bibliográficos
Autores principales: Becker, P S, Gooley, T A, Green, D J, Burwick, N, Kim, T Y, Kojouri, K, Inoue, Y, Moore, D J, Nelli, E, Dennie, T, Bensinger, W I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916300/
https://www.ncbi.nlm.nih.gov/pubmed/27176798
http://dx.doi.org/10.1038/bcj.2016.31

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916300/
https://www.ncbi.nlm.nih.gov/pubmed/27176798
http://dx.doi.org/10.1038/bcj.2016.31

Ejemplares similares